PADI4 polyclonal, anti-human

Protein Family: Enzymes

Pathway and Disease: Amino Acid Metabolism, Immune System, Transcription

Description:
Protein-arginine deiminase type-4 (PADI4) catalyzes the citrullination/deimination of arginine residues of proteins. PADI4 down-regulates histone H3 and H4 arginine methylation, both by preventing arginine methylation by CARM1 and HRMT1L2/PRMT1 and by converting methylarginine to citrulline. PADI4 is expressed in eosinophils and neutrophils but is not expressed in peripheral monocytes or lymphocytes. PADI4 is a rheumatoid arthritis susceptibility locus due to its important role in increasing citrullination of proteins in rheumatoid arthritis synovial tissues leading to a break in tolerance to citrullinated peptides processed and presented in the appropriate HLA context.

Alternate Names: PADI4, PAD4, Protein-arginine deiminase type IV, Protein-arginine deiminase type-4, Peptidylarginine deiminase IV, HL-60 PAD, PADI4

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500

Accession No.: Q9UM07

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human PADI4.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4 with 0.09% sodium azide. Antibody was purified by Protein-G affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.